Cancer Treatment Centers of America First in U.S. to Test Novel Nanotherapy for the Treatment of Lung Cancer
Learn More About This Topic: Chat with Us | Email Us
CTCA and Nanospectra Biosciences Announce Investigational Study of Using Nanoparticles to Kill Cancer Tumors from the Inside Out
PHILADELPHIA, PENN. (November 5, 2012) – Cancer Treatment Centers of America® (CTCA®) has announced that it will be the first center in the U.S. to conduct a clinical trial using advanced “nanotherapy” developed by Houston, Texas-based Nanospectra Biosciences, Inc. for the investigational treatment of primary and metastatic cancerous tumors in the lung. The pilot study, approved by the FDA and the CTCA Institutional Review Board, will allow cancer specialists at CTCA to use AuroLase Therapy, a new concept in the treatment of solid tumors that uses a system of near-infrared energy from a laser to heat up nanoparticles that are delivered to the tumor via the blood stream. The nanoparticles, called AuroShells, are absorbed by the tumor and not healthy tissue. The particles are engineered to convert infrared light into heat, thermally destroying the tumor while sparing any damage to healthy tissue.
“Cancer Treatment Centers of America is a leading cancer care organization that is committed to improving access to investigational cancer therapies for its patients,” said John Stroh, president and CEO, Nanospectra Biosciences. “We look forward to partnering with CTCA in order to bring our cutting edge NanoMedicine technology to more patients suffering from cancer.”
About Cancer Treatment Centers of America
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.